EUVIMEDEUVIMED entdecken
Multizentrische Studie

Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes

Melina Deban, Kadhim Taqi, Gregory C Knapp, Mikael Soucisse, Matt Curry, Lucas Sidéris, Pierre Dubé, Maher Al Khaldi, Nicole Jedrzejko, Geoff Porter, Carman Giacomantonio, Trevor Hamilton und 3 weitere

Journal of Surgical Oncology · 2023-09 · 128 (4) · 595-603

DOI: 10.1002/jso.27301 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Surgical Oncology, online erschienen am 30.05.2023. Verfasst von Melina Deban und 14 weiteren Autor:innen. Beteiligte Einrichtung: Tom Baker Cancer Center, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Hyperthermia, Induced, Mesothelioma, Malignant, Mesothelioma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Peritoneal mesothelioma (PM) is a rare malignancy originating from the peritoneal lining. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) is the standard‐of‐care for patients with isolated PM. Due to a paucity of prospective data there are several different HIPEC protocols. The aims of this study are to describe the CRS and HIPEC protocols for PM and patient outcomes across Canada.

Methods

A multicenter retrospective study was performed on patients diagnosed and treated for PM with CRS and HIPEC in four major peritoneal disease centers in Canada between 2000 and 2021. Data on patient characteristics, treatment patterns, postoperative morbidity, recurrence, and survival were collected.

Results

A total of 72 patients were identified. Mean age was 52 years (17–75) and 37.5% were male. Epithelioid (70.1%) and multicystic (13%) mesothelioma were the most common subtypes. Twenty‐one patients (30%) were treated with neoadjuvant chemotherapy. CRS and HIPEC was performed in 64 patients (91.4%). Of these, the mean PCI was 22 (2–39) and cisplatin+doxorubicin was the most common HIPEC regimen ( n = 33, 51.6%). A semi‐closed coliseum technique was used in 68.8% of HIPECs and the mean duration of surgery was 486 min (90–1052). Clavien‐Dindo III or IV complications occurred in 12 patients (16.9%). With a median follow‐up of 24 months (0.2–104.4), we found a 5‐year overall survival of 61% and a 5‐year recurrence‐free survival of 35%.

Conclusion

CRS and HIPEC is a safe and effective treatment modality for well‐selected patients with PM, with some achieving prolonged survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionHyperthermia, InducedMesothelioma, MalignantMesotheliomaPeritoneal NeoplasmsHumansMaleMiddle AgedFemaleRetrospective StudiesProspective StudiesCytoreduction Surgical ProceduresHyperthermic Intraperitoneal ChemotherapyCanadaAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapySurvival Rate

Stichwörter der Autor:innen

HIPECcytoreductive surgeryperitoneal mesotheliomasurvival

Autor:innen und Institutionen

  • Tom Baker Cancer Center, Calgary, Alberta, Canada.
  • Vancouver General Hospital, Vancouver, British Columbia, Canada.
  • QE II Health Sciences Center, Halifax, Nova Scotia, Canada.
  • Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada.

Zitieren

APA

Deban, M., Taqi, K., Knapp, G. C., Soucisse, M., Curry, M., Sidéris, L., Dubé, P., Khaldi, M. A., Jedrzejko, N., Porter, G., Giacomantonio, C., Hamilton, T., MacNeill, A., Mack, L., & Bouchard-Fortier, A. (2023). Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes. Journal of Surgical Oncology, 128(4), 595-603. https://doi.org/10.1002/jso.27301

Vancouver

Deban M, Taqi K, Knapp GC, Soucisse M, Curry M, Sidéris L, et al. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes. Journal of Surgical Oncology. 2023;128(4):595-603. doi:10.1002/jso.27301

BibTeX
@article{Deban2023,
  author = {Deban, Melina and Taqi, Kadhim and Knapp, Gregory C and Soucisse, Mikael and Curry, Matt and Sidéris, Lucas and Dubé, Pierre and Khaldi, Maher Al and Jedrzejko, Nicole and Porter, Geoff and Giacomantonio, Carman and Hamilton, Trevor and MacNeill, Andrea and Mack, Lloyd and Bouchard-Fortier, Antoine},
  title = {Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes},
  journal = {Journal of Surgical Oncology},
  year = {2023},
  volume = {128},
  number = {4},
  pages = {595--603},
  doi = {10.1002/jso.27301}
}
Kostenlos starten →